ArticleFrontiers in medicine2025
Brucellosis-associated hemophagocytic lymphohistiocytosis: a case report and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brucellosis associated with acute kidney injury and pancytopenia: a case report and review of the literature.Frontiers in medicine · 2026Article
- FulminantCase reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemophagocytic lymphohistiocytosis (HLH), a rare and deadly disease, is typically classified as either primary (familial) or secondary (acquired), depending on the etiology and underlying cause. Secondary HLH often develops in the presence of infectious, malignant, rheumatologic, or metabolic conditions, with infections, especially Case description: A 53-year-old man with brucellosis who developed secondary HLH and multiple organ dysfunction presented to our hospital with a 2-month history of fever and abnormal liver enzymes. Initial blood culture following admission confirmed Conclusion: Despite the generally poor prognosis of HLH patients, those with Brucella-induced HLH may have a favorable outcome with prompt intervention. Conversely, a delayed treatment could increase the risk of HLH onset and progression, leading to death in severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.